[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Jasper Therapeutics Inc. (JSPR)

Jasper Therapeutics Inc. (JSPR)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 19,273
  • Shares Outstanding, K 27,997
  • Annual Sales, $ 0 K
  • Annual Income, $ -75,800 K
  • EBIT $ -73 M
  • EBITDA $ -72 M
  • 60-Month Beta 3.07
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 6.00
  • Price/Earnings ttm 0.00
  • Earnings Per Share ttm -3.57
  • Most Recent Earnings $-0.38 on 05/14/26
  • Next Earnings Date 08/12/26 [--]
  • Annual Dividend & Yield (Fwd) 0.00 (0.00%)
  • Most Recent Dividend N/A on N/A
  • Sector Medical
  • INDUSTRY GROUPING Medical - Biomedical

Options Overview Details

View History
  • Implied Volatility 386.00% (+81.57%)
  • Historical Volatility 145.95%
  • IV Percentile 54%
  • IV Rank 27.99%
  • IV High 1,185.83% on 08/11/25
  • IV Low 75.16% on 03/03/26
  • Expected Move (DTE 26) 0.0510 (7.41%)
  • Put/Call Vol Ratio 2.19
  • Today's Volume 67
  • Volume Avg (30-Day) 169
  • Put/Call OI Ratio 0.58
  • Today's Open Interest 3,190
  • Open Int (30-Day) 3,631
  • Expected Range 0.6374 to 0.7394

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 7 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.38
  • Number of Estimates 2
  • High Estimate $-0.37
  • Low Estimate $-0.38
  • Prior Year $-1.74
  • Growth Rate Est. (year over year) +78.16%

Price Performance

See More
Period Period Low Period High Performance
1-Month
0.3151 +118.47%
on 06/29/26
1.0300 -33.17%
on 07/17/26
+0.1978 (+40.32%)
since 06/24/26
3-Month
0.3151 +118.47%
on 06/29/26
1.0300 -33.17%
on 07/17/26
-0.1500 (-17.89%)
since 04/24/26
52-Week
0.3151 +118.47%
on 06/29/26
3.2500 -78.82%
on 07/28/25
-2.4416 (-78.01%)
since 07/24/25

Most Recent Stories

More News
Jasper Therapeutics Announces Merger with Kira Pharmaceuticals

Combined company positioned to advance portfolio of biologic agents designed to improve outcomes in patients with numerous immunologically-driven disorders  Concurrent $132 million private investment...

JSPR : 0.6884 (-5.58%)
Jasper Therapeutics Announces Exploration of Strategic Alternatives to Maximize Shareholder Value

REDWOOD CITY, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody...

JSPR : 0.6884 (-5.58%)
Jasper Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

REDWOOD CITY, Calif., May 14, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody...

JSPR : 0.6884 (-5.58%)
Jasper Therapeutics Reports Fourth Quarter and Year-End 2025 Financial Results and Provides Corporate Update

REDWOOD CITY, Calif., March 30, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody...

JSPR : 0.6884 (-5.58%)
Jasper Therapeutics to Present at 46th Annual TD Cowen Healthcare Conference

REDWOOD CITY, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper), a clinical stage biotechnology company focused on development of briquilimab, a novel antibody...

JSPR : 0.6884 (-5.58%)
Jasper Therapeutics Reports Positive Updated Data from Briquilimab Studies in Chronic Spontaneous Urticaria

67% of additional patients (n=6) enrolled in the BEACON study achieved a complete response at 12 weeks with a mean UAS7 reduction of 31 points  75% of CSU participants (n=36) enrolled in the open...

JSPR : 0.6884 (-5.58%)
Jasper Therapeutics Appoints Jeet Mahal as Chief Executive Officer to Lead Next Phase of Clinical Growth

Thomas Wiggans appointed Executive Chairperson  Jasper to host an investor webinar on January 8 th at 8:00am ET to present updated data from the BEACON study in CSU and the open-label extension...

JSPR : 0.6884 (-5.58%)
Jasper Therapeutics Reports Positive Preliminary Data from ETESIAN Study of Briquilimab in Asthma and Findings from BEACON Study Internal Investigation

Reductions in airway hyperresponsiveness and suppressed eosinophilic response at both 6 weeks and 12 weeks observed after a single 180mg dose of Briquilimab in the ETESIAN Study Preliminary data from...

JSPR : 0.6884 (-5.58%)
Jasper Therapeutics to Host an Investor Webinar on December 2nd to Present Preliminary Data from ETESIAN Study in Asthma and Findings from BEACON Study Investigation

REDWOOD CITY, Calif., Dec. 01, 2025 (GLOBE NEWSWIRE) -- Jasper Therapeutics, Inc. (Nasdaq: JSPR) (Jasper or the Company), a clinical stage biotechnology company focused on development of briquilimab,...

JSPR : 0.6884 (-5.58%)
JSPR FINAL DEADLINE ALERT: Faruqi & Faruqi, LLP Announces that Jasper Therapeutics Investors Have Opportunity to Lead Class Action Lawsuit

Faruqi & Faruqi, LLP Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses In Jasper To Contact Him Directly To Discuss Their Options...

JSPR : 0.6884 (-5.58%)

Business Summary

Jasper Therapeutics Inc., a biotechnology company focused on hematopoietic cell transplant therapies. Jasper Therapeutics Inc., formerly known as Amplitude Healthcare Acquisition Corporation, is based in REDWOOD CITY, Calif.

See More

Key Turning Points

3rd Resistance Point 0.7838
2nd Resistance Point 0.7617
1st Resistance Point 0.7251
Last Price 0.6884
1st Support Level 0.6664
2nd Support Level 0.6443
3rd Support Level 0.6077

See More

52-Week High 3.2500
Fibonacci 61.8% 2.1289
Fibonacci 50% 1.7825
Fibonacci 38.2% 1.4362
Last Price 0.6884
52-Week Low 0.3151

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.